The company said that the technology is to be housed in Catalent’s Research Triangle Park, North Carolina facility, provides a flexible platform to reliably support all clinical manufacture through Phase II/III and a scaleable path to higher volume late stage clinical and commercial manufacturing.
Harro Hofliger claims that its equipment is an advanced technology specialised in powder filling for microdosing, in the 1 – 300mg of powder range, into an array of DPI formats to include both capsule-based and pre-metered blister device formats.
Reportedly, the new capability gives Catalent a full range of pulmonary and nasal services, filling a gap in the marketplace for advanced powder filling capabilities. Catalent will now be able to serve as a one-stop-shop for the development of all inhalation dosage forms, possessing both the capital assets and technical experience.